- Home
- TCRX vs HLVX Comparison
TCRX vs HLVX Comparison
Compare TCRX & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- HLVX
- Stock Information
- Founded
- TCRX 2018
- HLVX 2020
- Country
- TCRX United States
- HLVX United States
- Employees
- TCRX N/A
- HLVX N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- TCRX Health Care
- HLVX Health Care
- Exchange
- TCRX Nasdaq
- HLVX Nasdaq
- Market Cap
- TCRX 90.5M
- HLVX 83.7M
- IPO Year
- TCRX 2021
- HLVX 2022
- Fundamental
- Price
- TCRX $1.38
- HLVX $1.91
- Analyst Decision
- TCRX Strong Buy
- HLVX Hold
- Analyst Count
- TCRX 7
- HLVX 5
- Target Price
- TCRX $9.86
- HLVX $2.33
- AVG Volume (30 Days)
- TCRX 396.8K
- HLVX 298.1K
- Earning Date
- TCRX 05-06-2025
- HLVX 05-08-2025
- Dividend Yield
- TCRX N/A
- HLVX N/A
- EPS Growth
- TCRX N/A
- HLVX N/A
- EPS
- TCRX N/A
- HLVX N/A
- Revenue
- TCRX $4,421,000.00
- HLVX N/A
- Revenue This Year
- TCRX $47.30
- HLVX N/A
- Revenue Next Year
- TCRX $74.30
- HLVX N/A
- P/E Ratio
- TCRX N/A
- HLVX N/A
- Revenue Growth
- TCRX N/A
- HLVX N/A
- 52 Week Low
- TCRX $1.02
- HLVX $1.34
- 52 Week High
- TCRX $9.69
- HLVX $16.31
- Technical
- Relative Strength Index (RSI)
- TCRX 42.86
- HLVX 61.71
- Support Level
- TCRX $1.32
- HLVX $1.81
- Resistance Level
- TCRX $1.65
- HLVX $1.94
- Average True Range (ATR)
- TCRX 0.13
- HLVX 0.10
- MACD
- TCRX -0.01
- HLVX 0.01
- Stochastic Oscillator
- TCRX 14.63
- HLVX 83.87
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.